PUBLICATION

Original Articles

  • “Exocyst complex component 2 is a potential host factor for SARS-CoV-2 infection.” Yi, R., Hashimoto, R., Sakamoto, A., Matsumura, Y., Nagao, M., Takahashi, K., Takayama, K. iScience 25, 105427 (2022). doi.org/10.1016/j.isci.2022.105427
  • “Improved Sendai viral system for reprogramming to naive pluripotency.” Kunitomi, A., Hirohata, R., Arreola, V., Osawa, M., Kato, KM., Nomura, M., Kawaguchi, J., Hara, H., Kusano, K., Takashima, Y., Takahashi, K., Fukuda, K., Takasu, N., Yamanaka, S. Cell Reports Methods 17, 100317 (2022). doi.org/10.1016/j.crmeth.2022.100317
  • “Multi-omics approach reveals posttranscriptionally regulated genes are essential for human pluripotent stem cells.” Iwasaki, M., Kawahara, Y., Okubo, C., Yamakawa, T., Nakamura, M., Tabata, T., Nishi, Y., Narita, M., Ohta, A., Saito, H., Yamamoto, T., Nakagawa, M., Yamanaka, S., Takahashi, K. iScience 25, 104289 (2022). doi.org/10.1016/j.isci.2022.104289
  • “A stress-reduced passaging technique improves the viability of human pluripotent cells.” Takahashi, K., Okubo, C., Nakamura, M., Iwasaki, M., Kawahara, Y., Tabata, T., Miyamoto, Y., Woltjen, K., Yamanaka, S. Cell Reports Methods 2, 100155 (2022). doi.org/10.1016/j.crmeth.2021.100155
  • “Dual inhibition of TMPRSS2 and Cathepsin B prevents SARS-CoV-2 infection in iPS cells.” Hashimoto, R., Sakamoto, A., Deguchi, S., Yi, R., Sano, E., Hotta, A., Takahashi, K., Yamanaka, S., Takayama, K. Molecular Therapy Nucleic Acids (2021). doi.org/10.1016/j.omtn.2021.10.016
  • “The pluripotent stem cell-specific transcript ESRG is dispensable for human pluripotency.” Takahashi, K., Nakamura, M., Okubo, C., Kliesmete, Z., Ohnuki, M., Narita, M., Watanabe, A., Ueda, M., Takashima, Y., Hellmann, I., Yamanaka, S. PLoS Genetics 17: e1009587 (2021).
  • “Critical roles of translation initiation and RNA uridylation in endogenous retroviral expression and neural differentiation in pluripotent stem cells.” Takahashi, K., Jeong, D., Wang, S., Narita, M., Jin, X., Iwasaki, M., Perli, SD., Conklin, BR., Yamanaka, S. Cell Reports 31, 107715 (2020).
  • “Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells.” International Stem Cell Initiative. Allison,TF., Andrews, PW., Avior, Y., Barbaric, I., Benvenisty, N., Bock, C., Brehm, J., Brüstle, O., Damjanov, I., Elefanty, A., Felkner, D., Gokhale, PJ., Halbritter, F., Healy, LE., Hu, TX., Knowles, BB., Loring, JF., Ludwig, TE., Mayberry, R., Micallef, S., Mohamed, JS., Müller, FJ., Mummery, CL., Nakatsuji, N., Ng, ES., Oh, SKW., O’Shea, O., Pera, MF., Reubinoff, B., Robson, P., Rossant, J., Schuldt, BM., Solter, D., Sourris, K., Stacey, G., Stanley, EG., Suemori, H., Takahashi, K., Yamanaka, S. Nature Communications 9, 1925 (2018).
  • “MYC Releases Early Reprogrammed Human Cells from Proliferation Pause via Retinoblastoma Protein Inhibition.” Rand, TA., Sutou, K., Tanabe, K., Jeong, D., Nomura, M., Kitaoka, F., Tomoda, E., Narita, M., Nakamura, M., Nakamura, M., Watanabe, A., Rulifson, E., Yamanaka, S., Takahashi, K. Cell Reports 23, 361-375 (2018).
  • “Nat1 promotes translation of specific proteins that induce differentiation of mouse embryonic stem cells.” Sugiyama, H., Takahashi, K., Yamamoto, T., Iwasaki, M., Narita, M., Nakamura, M., Rand, TA., Nakagawa, M., Watanabe, A., Yamanaka, S. Proceedings of the National Academy of Sciences of the U. S. A. 114, 340-345 (2017).
  • “Identification of MMP1 as a novel risk factor for intracranial aneurysms in ADPKD using iPSC models.” Ameku, T., Taura, D., Sone, M., Numata, T., Nakamura, M., Shiota, F., Toyoda, T., Matsui, S., Araoka, T., Yasuno, T., Mae, S., Kobayashi, H., Kondo, N., Kitaoka, F., Amano, N., Arai, S., Ichisaka, T., Matsuura, N., Inoue, S., Yamamoto, T., Takahashi, K., Asaka, I., Yamada, Y., Ubara, Y., Muso, E., Fukatsu, A., Watanabe, A., Sato, Y., Nakahata, T., Mori, Y., Koizumi, A., Nakao, K., Yamanaka, S., Osafune, K. Scientific Reports 6, 30013 (2016).
  • “Cell Therapy Using Human Induced Pluripotent Stem Cell-Derived Renal Progenitors Ameliorates Acute Kidney Injury in Mice.” Toyohara, T., Mae, S., Sueta, S., Inoue, T., Yamagishi, Y., Kawamoto, T., Kasahara, T., Hoshina, A., Toyoda, T., Tanaka, H., Araoka, T., Sato-Otsubo, A., Takahashi, K., Sato, Y., Yamaji, N., Ogawa, S., Yamanaka, S., Osafune, K. Stem Cells Translational Medicine 4, 980-992 (2015).
  • “Robust In Vitro Induction of Human Germ Cell Fate from Pluripotent Stem Cells.” Sasaki, K., Yokobayashi, S. Nakamura, T., Okamoto, I., Yabuta, Y., Kurimoto, K., Ohta, H., Moritoki, Y., Iwatani, C., Tsuchiya, H., Nakamura, S., Sekiguchi, K., Sakuma, T., Yamamoto, T., Mori, T., Woltjen, K., Nakagawa, M., Yamamoto, T., Takahashi, K., Yamanaka, S., Saitou, M. Cell Stem Cell 17, 178-194 (2015).
  • “The homeobox gene DLX4 promotes generation of human induced pluripotent stem cells.” Tamaoki, N., Takahashi, K., Aoki, H., Iida, K., Kawaguchi, T., Hatakeyama, D., Inden, M., Chosa, N., Ishisaki, A., Kunisada, T., Shibata, T., Goshima, N., Yamanaka, S., Tezuka, KI. Scientific Reports 4, doi:10.1038/srep07283 (2014).
  • “Dynamic Regulation of Human Endogenous Retroviruses Mediates Factor-induced Reprogramming and Differentiation Potential.” Ohnuki, M., Tanabe, K., Sutou, K., Teramoto, I., Sawamura, Y., Narita, M., Nakamura, M., Tokunaga, Y., Nakamura, M., Watanabe, A., Yamanaka, S., Takahashi, K. Proceedings of the National Academy of Sciences of the U. S. A. 111, 12426-12431 (2014).
  • “Involvement of ER Stress in Dysmyelination of Pelizaeus-Merzbacher Disease with PLP1 Missense Mutations Shown by iPSC-Derived Oligodendrocytes.” Numasawa-Kuroiwa, Y., Okada, Y., Shibata, S., Kishi, N., Akamatsu, W., Shoji, M., Nakanishi, A., Oyama, M., Osaka, H., Inoue, K., Takahashi, K., Yamanaka, S., Kosaki, K., Takahashi, T., Okano, H. Stem Cell Reports 2, 1-14 (2014).
  • “Induction of pluripotency in human somatic cells via a transient state resembling primitive streak-like mesendoderm.” Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Sasaki, A., Yamamoto, M., Nakamura, M., Sutou, K., Osafune, K., Yamanaka, S. Nature Communications 5, 3678 (2014).
  • “The let-7/LIN-41 Pathway Regulates Reprogramming to Human Induced Pluripotent Stem Cells by Controlling Expression of Prodifferentiation Genes.” Worringer, KA., Rand, TA., Hayashi, Y., Sami, S., Takahashi, K., Tanabe, K., Narita, M., Srivastava, D., Yamanaka, S. Cell Stem Cell 14, 40-52 (2014).
  • “Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells.” Koyanagi-Aoi, M., Ohnuki, M., Takahashi, K., Okita, K., Noma, H., Sawamura, Y., Teramoto, I., Narita, M., Sato, Y., Ichisaka, T., Amano, N., Watanabe, A., Morizane, A., Yamada, Y., Sato, T., Takahashi, J., Yamanaka, S. Proceedings of the National Academy of Sciences of the U. S. A. 110, 20569-20574 (2013).
  • “Maturation, not initiation, is the major roadblock during reprogramming toward pluripotency from human fibroblasts.” Tanabe, K., Nakamura, M., Narita, M., Takahashi, K., Yamanaka, S. Proceedings of the National Academy of Sciences of the U. S. A. 110, 12172-12179 (2013).
  • “Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells.” Yamashita, A., Liu, S., Woltjen, K., Thomas, B., Meng, G., Hotta, A., Takahashi, K., Ellis, J., Yamanaka, S., Rancourt, DE. Scientific Reports 3, 1978 (2013).
  • “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.” Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., Takahashi, K., Asaka, I., Aoi, T., Watanabe, A., Watanabe, K., Kadoya, C., Nakano, R., Watanabe, D., Maruyama, K., Hori, O., Hibino, S., Choshi, T., Nakahata, T., Hioki, H., Kaneko, T., Naitoh, M., Yoshikawa, K., Yamawaki, S., Suzuki, S., Hata, R., Ueno, S., Seki, T., Kobayashi, K., Toda, T., Murakami, K., Irie, K., Klein, WL., Mori, H., Asada, T., Takahashi, R., Iwata, N., Yamanaka, S., Inoue, H. Cell Stem Cell 12, 487-496 (2013).
  • “Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells.” Mae, S., Shono, A., Shiota, F., Yasuno, T., Kajiwara, M., Gotoda-Nishimura, N., Arai, S., Sato-Otubo, A., Toyoda, T., Takahashi, K., Nakayama, N., Cowan, CA., Aoi, T., Ogawa, S., McMahon, AP., Yamanaka, S., Osafune, K. Nature Communications 4, 1367 (2013).
  • “Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery.” Tanaka, T., Takahashi, K., Yamane, M., Tomida, S., Nakamura, S., Oshima, K., Niwa, A., Nishikomori, R., Kambe, N., Hara, H., Mitsuyama, M., Morone, N., Heuse,r JE., Yamamoto, T., Watanabe, A., Sato-Otsubo, A., Ogawa, S., Asaka, I., Heike, T., Yamanaka, S., Nakahata, T., Saito, MK. Blood 120, 1299-1308 (2012).
  • “Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells.” Tomoda, K., Takahashi, K., Leung, K., Okada, A., Narita, M., Yamada, NA., Eilertson, KE., Tsang, P., Baba, S., White, MP., Sami, S., Srivastava, D., Conklin, BR., Panning, B., Yamanaka, S. Cell Stem Cell 11, 91-99 (2012).
  • “Drug screening for ALS using patient-specific induced pluripotent stem cells.” Egawa, N., Kitaoka, S., Tsukita, K., Naitoh, M., Takahashi, K., Yamamoto, T., Adachi, F., Kondo, T., Okita, K., Asaka, I., Aoi, T., Watanabe, A., Yamada, Y., Morizane, A., Takahashi, J., Ayaki, T., Ito, H., Yoshikawa, K., Yamawaki, S., Suzuki, S., Watanabe, D., Hioki, H., Kaneko, T., Makioka, K., Okamoto, K., Takuma, H., Tamaoka, A., Hasegawa, K., Nonaka, T., Hasegawa, M., Kawata, A., Yoshida, M., Nakahata, T., Takahashi, R., Marchetto, MC., Gage, FH., Yamanaka, S., Inoue, H. Science Translational Medicine 4, 145ra104 (2012).
  • “Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage.” International stem cell initiative. Amps, K., Andrews, PW., Anyfantis, G., Armstrong, L., Avery, S., Baharvand, H., Baker, J., Baker, D., Munoz, MB., Beil, S., Benvenisty, N., Ben-Yosef, D., Biancotti, JC., Bosman, A., Brena, RM., Brison, D., Caisander, G., Camarasa, MV., Chen, J., Chiao, E., Choi, YM., Choo, ABH., Collins, D., Colman, A., Crook, JM., Daley, GQ., Dalton, A., De Sousa, PA., Denning, C., Downie, J., Dvorak, P., Montgomery, KD., Feki, A., Ford, A., Fox, V., Fraga, AM., Frumkin, T., Ge, L., Gokhale, PJ., Golan-Lev, T., Gourabi, H., Gropp, M., Lu, G., Hampl, A., Harron, K., Healy, L., Herath, W., Holm, F., Hovatta, O., Hyllner, J., Inamdar, MS., Irwanto, AK., Ishii, T., Jaconi, M., Jin, Y., Kimber, S., Kiselev, S., Knowles, BB., Kopper, O., Kukharenko, V., Kuliev, A., Lagarkova, MA., Laird, PW., Lako, M., Laslett, AL., Lavon, N., Lee, DR., Lee, JE., Li, C., Lim, LS., Ludwig, TE., Ma, Y., Maltby, E., Mateizel, I., Mayshar, Y., Mileikovsky, M., Minger, SL., Miyazaki, T., Moon, SY., Moore, H., Mummery, C., Nagy, A., Nakatsuji, N., Narwani, K., Oh, SKW., Oh, SK., Olson, C., Otonkoski, T., Pan, F., Park, IH., Pells, S., Pera, MF., Pereira, LV., Qi, O., Raj, GS., Reubinoff, B., Robins, A., Robson, P., Rossant, J., Salekdeh, GH., Schulz, TC., Sermon, K., Mohamed, JS., Shen, H., Sherrer, E., Sidhu, K., Sivarajah, S., Skottman, H., Spits, C., Stacey, GN., Strehl, R., Strelchenko, N., Suemori, H., Sun, B., Suuronen, R., Takahashi, K., Tuuri, T., Venu, P., Verlinsky, Y., Oostwaard, DW., Weisenberger, DJ., Wu, Y., Yamanaka, S., Young, L., Zhou, Q. Nature biotechnology 29, 1132-1144 (2011).
  • “Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-a.” Fujiwara, M., Yan, P., Otsuji, T.G., Narazaki, G., Uosaki, H., Fukushima, H., Kuwahara, K., Harada, M., Matsuda, H., Matsuoka, S., Okita, K., Takahashi, K., Nakagawa, M., Ikeda, T., Sakata, R., Mummery, C.L., Nakatsuji, N., Yamanaka, S., Nakao, K., Yamashita, J.K. PLoS ONE 6, e16734 (2011).
  • “Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease.” Yahata, N., Asai, M., Kitaoka, S., Takahashi, K., Asaka, I., Hioki, H., Kaneko, T., Maruyama, K., Saido, TC., Nakahata, T., Asada, T., Yamanaka, S., Iwata, N., Inoue, H. PLoS ONE 6, e25788 (2011).
  • “ECAT11/L1td1 is enriched in ESCs and rapidly activated during iPSC generation, but it is dispensable for the maintenance and induction of pluripotency.” Iwabuchi, KA., Yamakawa, T., Sato, Y., Ichisaka, T., Takahashi, K., Okita, K., Yamanaka, S. PLoS ONE 6, e20461 (2011).
  • “Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells.” Takayama, N., Nishimura, S., Nakamura, S., Shimizu, T., Ohnishi, R., Endo, H., Yamaguchi, T., Otsu, M., Nishimura, K., Nakanishi, M., Sawaguchi, A., Nagai, R., Takahashi, K., Yamanaka, S., Nakauchi, H., Eto, K. Journal of Experimental Medicine 20, 2817-2830 (2010).
  • “Sirt1 plays an important role in mediating greater functionality of human ES/iPS-derived vascular endothelial cells.” Homma, K., Sone, M., Taura, D., Yamahara, K., Suzuki, Y., Takahashi, K., Sonoyama, T., Inuzuka, M., Fukunaga, Y., Tamura, N., Itoh, H., Yamanaka, S., Nakao, K. Atherosclerosis 212, 42-47 (2010).
  • “Dental Pulp Cells for Induced Pluripotent Stem Cell Banking.” Tamaoki, N., Takahashi, K., Tanaka, T., Ichisaka, T., Aoki, H., Takeda-Kawaguchi, T., Iida, K., Kunisada, T., Shibata, T., Yamanaka, S., Tezuka, K. Journal of Dental Research 89, 773-778 (2010).
  • “Generation of mouse-induced pluripotent stem cells with plasmid vectors.” Okita, K., Hong, H., Takahashi, K., Yamanaka, S. Nature Protocols 5, 418-428 (2010).
  • “Complete genetic correction of iPS cells from Duchenne muscular dystrophy.” Kazuki, Y., Hiratsuka, M., Takiguchi, M., Osaki, M., Kajitani, N., Hoshiya, H., Hiramatsu, K., Yoshino, T., Kazuki, K., Ishihara, C., Takehara, S., Higaki, K., Nakagawa, M., Takahashi, K., Yamanaka, S., Oshimura, M. Molecular Therapy 18, 386-393 (2010).
  • “Human induced Pluripotent Stem cells on autologous feeders.” Takahashi, K., Narita, M., Yokura, M., Ichisaka, T., Yamanaka, S. PLoS ONE 4, e8067 (2009).
  • “Hypoxia enhances the generation of induced pluripotent stem cells.” Yoshida, Y., Takahashi, K., Okita, K., Ichisaka, T., Yamanaka, S. Cell Stem Cell 5, 237-241 (2009).
  • “Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.” Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., Yamanaka, S. Nature 460, 1132-1135 (2009).
  • “ERas is expressed in primate embryonic stem cells but not related to tumorigenesis.” Tanaka, Y., Ikeda, T., Kishi, Y., Masuda, S., Shibata, H., Takeuchi, K., Komura, M., Iwanaka, T., Muramatsu, S., Kondo, Y., Takahashi, K., Yamanaka, S., Hanazono,Y. Cell Transplantation 18, 381-389 (2009).
  • “Orderly hematopoietic development of induced pluripotent stem cells via Flk-1(+) hemoangiogenic progenitors.” Niwa, A., Umeda, K., Chang, H., Saito, M., Okita, K., Takahashi, K., Nakagawa, M., Yamanaka, S., Nakahata, T., Heike, T. Journal of Cell Physiology 221, 367-377 (2009).
  • “Induction and isolation of vascular cells from human induced pluripotent stem cells.” Taura, D., Sone, M., Homma, K., Oyamada, N., Takahashi, K., Tamura, N., Yamanaka, S., Nakao, K. Arteriosclerosis Thrombosis Vascular Biology 29, 1100-1103 (2009).
  • “Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells.” Senju, S., Haruta, M., Matsunaga, Y., Fukushima, S., Ikeda, T., Takahashi, K., Okita, K., Yamanaka, S., Nishimura, Y. Stem Cells 27, 1021-1031 (2009).
  • “Generation of retinal cells from mouse and human induced pluripotent stem cells.” Hirami, Y., Osakada, F., Takahashi, K., Okita, K., Yamanaka, S., Ikeda, H., Yoshimura, N., Takahashi, M. Neuroscience Letter 458, 126-131 (2009).
  • “Adipogenic differentiation of human induced pluripotent stem cells: comparison with that of human embryonic stem cells.” Taura, D., Noguchi, M., Sone, M., Hosoda, K., Mori, E., Okada, Y., Takahashi, K., Homma, K., Oyamada, N., Inuzuka, M., Sonoyama, T., Ebihara, K., Tamura, N., Itoh, H., Suemori, H., Nakatsuji, N., Okano, H., Yamanaka, S., Nakao, K. FEBS Letter 583, 1029-1033 (2009).
  • “Variation in the safety of induced pluripotent stem cell lines.” Miura, K., Okada, Y., Aoi, T., Okada. A., Takahashi, K., Okita, K., Nakagawa, M., Koyanagi, M., Tanabe, K., Ohnuki, M., Ogawa, D., Ikeda, E., Okano, H., Yamanaka, S. Nature Biotechnology 27, 743-745 (2009).
  • “Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts.” Tsubooka, N., Ichisaka, T., Okita, K., Takahashi, K., Nakagawa, M., Yamanaka, S. Genes to Cells 14, 683-694 (2009).
  • “Generation of pluripotent stem cells from adult mouse liver and stomach cells.” Aoi, T., Yae, K., Nakagawa, M., Ichisaka, T., Okita, K., Takahashi, K., Chiba, T., Yamanaka, S. Science 321, 699-702 (2008).
  • “Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts.” Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., Mochiduki, Y., Takizawa, N., Yamanaka, S. Nature Biotechnology 26, 101-106 (2008).
  • “Induction of Pluripotent Stem Cells from Fibroblast Cultures.” Takahashi, K., Okita, K., Nakagawa, M., Yamanaka, S. Nature Protocols 2, 3081-3089 (2007).
  • “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors.” Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S. Cell 131, 861-872 (2007).
  • “Induction of Pluripotent Stem Cells from Embryonic and Adult Fibroblast Cultures by Defined Factors.” Takahashi, K., Yamanaka, S. Cell 126, 663-676 (2006).
  • “Differential membrane localization of ERas and Rheb, Two Ras-related proteins involved in the PI3 kinase/mTOR pathway.” Takahashi, K., Nakagawa, M., Young, SG., Yamanaka, S. Journal of Biological Chemistry 280, 32768-32774 (2005).
  • “Evolutionarily Conserved Non-AUG Translation Initiation in NAT1/p97/DAP5 (EIF4G2).” Takahashi, K., Maruyama, M., Tokuzawa, Y., Murakami, M., Oda, Y., Yoshikane, N., Makabe, KW., Ichisaka, T., Yamanaka, S. Genomics 85, 360-367 (2005).
  • “The Homeoprotein NANOG is Required for Maintenance of Pluripotency in Mouse Epiblast and ES Cells.” Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., Maruyama, M., Maeda, M., Yamanaka, S.” Cell 113, 631-642 (2003).
  • “Role of ERas in promoting tumor-like properties in mouse embryonic stem cells.” Takahashi, K., Mitsui, K., Yamanaka, S. Nature 423, 541-545 (2003).
  • “Fbx15 is a novel target of Oct3/4 but is dispensable for ES cell self-renewal and mouse development.” Tokuzawa, Y., Kaiho, E., Maruyama, M., Takahashi, K., Mitsui, K., Maeda, M., Niwa, H., Yamanaka, S. Molecular and Cellular Biology 23, 2699-2708 (2003).

Reviews and Book Chapters

  • “Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development.” Karagiannis, P., Takahashi, K., Saito, M., Yoshida, Y., Okita, K., Watanabe, A., Inoue, H., Yamashita, JK., Todani, M., Nakagawa, M., Osawa, M., Yashiro, Y., Yamanaka, S., Osafune, K. Physiological Reviews 99, 79-114 (2019).
  • “A decade of transcription factor-mediated reprogramming to pluripotency.” Takahashi, K., Yamanaka, S. Nature Reviews Molecular Cell Biology 17, 183-193 (2016).
  • “Developmental Framework of Induced Pluripotency.” Takahashi, K., Yamanaka, S. Development 142, 3274-3285 (2015).
  • “Present and Future Challenges of Induced Pluripotent Stem Cells.” Ohnuki, M., Takahashi, K. Philosophical Transactions Royal Society B 370, pii: 20140367 (2015).
  • “Induction of pluripotency by defined factors.” Tanabe, K., Takahashi, K., Yamanaka, S. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences 90, 83-96 (2014).
  • “Cellular reprogramming.” Takahashi, K. Epigenetics: Cold Spring Harbor Perspectives 6, a018606 (2014).
  • “Induced pluripotent stem cells in biology and medicine.” Takahashi, K., Yamanaka, S. Development 140, 2457-2461 (2013).
  • “Induced Pluripotent Stem Cells.” Okita, K., Takahashi, K., Yamanaka, S. Regenerative Medicine: From Protocol to Patient Chapter 8, 197-218 (2013).
  • “Induced Pluripotent Stem Cells.” Takahashi, K., Yamanaka, S. Encyclopedia of Molecular Cell Biology and Molecular Medicine (2012).
  • “Cellular reprogramming--lowering gravity on Waddington's epigenetic landscape.” Takahashi, K. Journal of Cell Science 125, 2553-2560 (2012).
  • “Beginning of Chapter II.” Takahashi, K. Cell Stem Cell 11, 740 (2012).
  • “Derivation of Human Induced Pluripotent Stem Cells on Autologous Feeders.” Takahashi, K. Human Embryonic and Induced Pluripotent Stem Cells: Lineage-Specific Differentiation Protocols Chapter 13, 161-171 (2012).
  • “Induced Pluripotent Stem Cells.” Takahashi, K., Yamanaka, S. Regenerative Medicine: From Protocol to Patient Chapter 8, 187-205 (2011).
  • “Direct reprogramming 101.” Takahashi, K. Development, Growth and Differentiation 52, 319-333 (2010).
  • “Generation and characterization of human induced pluripotent stem cells.” Ohnuki, M., Takahashi, K., Yamanaka, S. Current protocol in Stem Cell Biology Chapter 4, Unit 4A2 (2009).
  • “Identification of genes involved in tumor-like properties of ES cells.” Takahashi, K., Ichisaka, T., Yamanaka, S. Method in Molecular Biology, Embryonic Stem Cells-II: Methods and Protocols 329, 447-458 (2006).
  • “Role of the phosphoinositide 3-kinase pathway in mouse embryonic stem (ES) cells.” Takahashi, K., Murakami, M., Yamanaka, S. Biochemical Society Transactions 33, 1522-1525 (2005).

Reviews and Book Chapters in Japanese

  • “iPS細胞までの道のり” 高橋 和利, 実験医学 38, 8-13 (2020).
  • “個人の組織から分離された線維芽細胞及びそれらから作成されたiPS細胞のエピジェネティッククロック解析” 堀江 信之、高橋 和利、加治 和彦 Journal of Nagoya Women’s University 65, 27-38 (2019).
  • “iPS細胞研究最前線” 高橋 和利、山中 伸弥 先進医療NAVIGATOR「今日の再生医療・細胞医療の産業化に向けて」 Chapter 1, Unit 2 (2017).
  • “ヒト多能性幹細胞” 須藤 健太、高橋 和利 実験医学 増刊 33, 168-173 (2015).
  • “医療用iPS細胞の評価” 高橋 和利 再生医療 13, 378-388 (2014).
  • “iPS細胞研究の展望と課題” 高橋 和利 最新医学 69, 539-546 (2014).
  • “臨床応用を目指したiPS細胞の樹立” 須藤 健太、高橋 和利 Medical Science Digest 39, 507-509 (2013).
  • “iPS細胞とは” 須藤 健太、高橋 和利 整形外科 64, 566-568 (2013).
  • “人工多能性幹細胞” 高橋 和利 再生医療業書 幹細胞 49-69 (2012).
  • “iPS細胞の樹立方法” 沖田 圭介、高橋 和利 再生医療 8, 47-53 (2009).
  • “iPS細胞樹立の実際” 高橋 和利 細胞工学 28, 200-203 (2009).
  • “人工多能性幹細胞 (iPS細胞)” 高橋 和利、山中 伸弥 実験医学 増刊 26, 643-648 (2008).
  • “ヒト人工多能性幹細胞の樹立” 高橋 和利、山中 伸弥 細胞工学 27, 252-253 (2008).
  • “遺伝子導入による万能細胞の作製” 高橋 和利、沖田 圭介、山中 伸弥 関節外科 26, 1191-1192 (2008).
  • “遺伝子導入による万能細胞の作製” 高橋 和利、沖田 圭介、山中 伸弥 再生医療 6, 284-289 (2008).
  • “体細胞培養から誘導される人工万能幹細胞” 高橋 和利、山中 伸弥 細胞工学 26, 489-492 (2007).
  • “特定因子による多能性幹細胞の誘導” 高橋 和利、山中 伸弥 実験医学 25, 479-483 (2007).
  • “分化した体細胞から人工万能幹細胞を作製・iPS細胞の可能性と課題” 山中 伸弥、高橋 和利 科学 76, 1177-1179 (2006).
  • “マウス線維芽細胞から誘導多能性幹細胞をつくる” 山中 伸弥、高橋 和利 PNE 蛋白質 核酸 酵素 51, 2346-2351 (2006).
  • “人工万能幹細胞 (iPS細胞) の樹立と課題” 山中 伸弥、高橋 和利 細胞工学 25, 1288-1289 (2006).
  • “ERasによるES細胞の腫瘍形成制御機構” 高橋 和利、村上 未玲、一阪 朋子、山中 伸弥 細胞工学 24, 17-19 (2003).
  • “ES細胞で特異的に機能する”癌遺伝子”ERas” 高橋 和利、山中 伸弥 実験医学 21, 1757-9 (2003).
  • “ES細胞の腫瘍形成能を促進する新規Ras遺伝子ERas” 高橋 和利、山中 伸弥 細胞工学 22, 768-769 (2003).